DK1117435T3 - Muteret cholera-holotoxin som adjuvans - Google Patents

Muteret cholera-holotoxin som adjuvans

Info

Publication number: DK1117435T3
Authority: DK; Denmark
Prior art keywords: adjuvant; amino acid; holotoxin; cholera holotoxin; mutant cholera
Prior art date: 1998-09-30

Application number

DK99951639T

Other languages

Danish (da)

English (en)

Inventor

Randall K Holmes

John H Eldridge

Bruce A Green

Gerald E Hancock

Joel A Peek

Michael G Jobling

Original Assignee

Wyeth Corp

Us Gov Univ Health Sciences

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-09-30

Filing date

1999-09-30

Publication date

2008-03-17

1999-09-30 Application filed by Wyeth Corp, Us Gov Univ Health Sciences filed Critical Wyeth Corp

2008-03-17 Application granted granted Critical

2008-03-17 Publication of DK1117435T3 publication Critical patent/DK1117435T3/da

Links

206010008631 Cholera Diseases 0.000 title abstract 4
239000002671 adjuvant Substances 0.000 title abstract 3
235000001014 amino acid Nutrition 0.000 abstract 4
150000001413 amino acids Chemical class 0.000 abstract 4
229930186900 holotoxin Natural products 0.000 abstract 3
230000000890 antigenic effect Effects 0.000 abstract 2
230000035772 mutation Effects 0.000 abstract 2
241000233866 Fungi Species 0.000 abstract 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 abstract 1
241000251539 Vertebrata <Metazoa> Species 0.000 abstract 1
241000700605 Viruses Species 0.000 abstract 1
239000000427 antigen Substances 0.000 abstract 1
102000036639 antigens Human genes 0.000 abstract 1
108091007433 antigens Proteins 0.000 abstract 1
235000003704 aspartic acid Nutrition 0.000 abstract 1
244000052616 bacterial pathogen Species 0.000 abstract 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 abstract 1
125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 abstract 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 1
230000028993 immune response Effects 0.000 abstract 1
244000045947 parasite Species 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/15—Reoviridae, e.g. calf diarrhea virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/28—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12311—Rotavirus, e.g. rotavirus A
- C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Mycology (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Virology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pulmonology (AREA)
Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Biological Depolymerization Polymers (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Saccharide Compounds (AREA)

DK99951639T 1998-09-30 1999-09-30 Muteret cholera-holotoxin som adjuvans DK1117435T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US10243098P	1998-09-30	1998-09-30
PCT/US1999/022520 WO2000018434A1 (en)	1998-09-30	1999-09-30	Mutant cholera holotoxin as an adjuvant

Publications (1)

Publication Number	Publication Date
DK1117435T3 true DK1117435T3 (da)	2008-03-17

Family

ID=22289805

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK99951639T DK1117435T3 (da)	1998-09-30	1999-09-30	Muteret cholera-holotoxin som adjuvans

Country Status (16)

Country	Link
EP (1)	EP1117435B1 (ko)
JP (1)	JP4673974B2 (ko)
KR (1)	KR100659803B1 (ko)
CN (1)	CN1197618C (ko)
AT (1)	ATE378066T1 (ko)
AU (1)	AU770333B2 (ko)
BR (1)	BR9914160A (ko)
CA (1)	CA2344740C (ko)
CY (1)	CY1107276T1 (ko)
DE (1)	DE69937571T2 (ko)
DK (1)	DK1117435T3 (ko)
ES (1)	ES2293735T3 (ko)
IL (2)	IL142231A0 (ko)
MX (1)	MXPA01003228A (ko)
PT (1)	PT1117435E (ko)
WO (1)	WO2000018434A1 (ko)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9513371D0 (en)	1995-06-30	1995-09-06	Biocine Spa	Immunogenic detoxified mutant toxins
DK0725653T3 (da)	1993-10-05	2004-10-11	Celltech Pharmaceuticals Ltd	Vaccinepræparater
GB9326174D0 (en) *	1993-12-22	1994-02-23	Biocine Sclavo	Mucosal adjuvant
GB9622660D0 (en)	1996-10-31	1997-01-08	Biocine Spa	Immunogenic detoxified mutant toxin
US6818222B1 (en)	1997-03-21	2004-11-16	Chiron Corporation	Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
US7115730B1 (en)	1999-04-27	2006-10-03	Chiron Srl	Immunogenic detoxified mutant E. coli LT-A-toxin
AU2001268662A1 (en)	2000-06-23	2002-01-08	Wyeth Holdings Corporation	Assembly of wild-type and chimeric influenza virus-like particles (VLPs)
EP2402359A1 (en)	2000-12-28	2012-01-04	Wyeth LLC	Recombinant protective protein from streptococcus pneumoniae
KR20080081201A (ko)	2001-04-16	2008-09-08	와이어쓰 홀딩스 코포레이션	폴리펩티드 항원을 암호화하는 신규한 스트렙토코쿠스뉴모니애 개방형 판독 프레임 및 이를 포함하는 조성물
KR100898648B1 (ko)	2001-06-07	2009-05-22	와이어쓰 홀딩스 코포레이션	보조제로서 콜레라 홀로톡신의 돌연변이체 형태
KR20080078717A (ko)	2001-06-07	2008-08-27	와이어쓰 홀딩스 코포레이션	보조제로서 콜레라 홀로톡신의 돌연변이체 형태
AU2002355197A1 (en)	2001-07-27	2003-02-17	Chiron Srl	Meningococcus adhesins nada, app and orf 40
MX339524B (es)	2001-10-11	2016-05-30	Wyeth Corp	Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0129007D0 (en) *	2001-12-04	2002-01-23	Chiron Spa	Adjuvanted antigenic meningococcal compositions
JP2005532789A (ja)	2002-03-15	2005-11-04	ワイス・ホールデイングス・コーポレーシヨン	減少した酵素活性を有する型別不能なインフルエンザ菌（Ｈａｅｍｏｐｈｉｌｕｓｉｎｆｌｕｅｎｚａ）のＰ４タンパク質の変異体
US7785608B2 (en)	2002-08-30	2010-08-31	Wyeth Holdings Corporation	Immunogenic compositions for the prevention and treatment of meningococcal disease
EP1603950A2 (en) *	2003-03-17	2005-12-14	Wyeth Holdings Corporation	Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
AU2004233012A1 (en) *	2003-04-16	2004-11-04	Wyeth Holdings Corporation	Novel immunogenic compositions for the prevention and treatment of meningococcal disease
WO2005020902A2 (en)	2003-08-21	2005-03-10	Cytokine Pharmasciences, Inc.	Compositions and methods for treating and diagnosing irritable bowel syndrome
BRPI0417744B8 (pt)	2003-12-17	2021-05-25	Wyeth Corp	método para produzir um conjugado imunogênico, e,conjugado imunogênico
KR101158147B1 (ko)	2003-12-17	2012-07-17	와이어쓰 엘엘씨	Ａβ 면역원성 펩티드 캐리어 컨쥬게이트 및 이의 제조방법
GB0410220D0 (en)	2004-05-07	2004-06-09	Kirkham Lea Ann	Mutant pneumolysin proteins
BRPI0511429A (pt)	2004-05-21	2007-12-11	Wyeth Corp	proteìna de ligação à fibronectina (fnb) isolada, alterada de staphylococcal aureus (s. aureus); fnb isolada, alterada; composição imunogênica; método para imunizar um vertebrado contra s. aureus; vetor de expressão; célula hospedeira recombinante; método para produzir uma fnb alterada; método para induzir uma resposta imunológica em um vertebrado; proteìna isolada, alterada de ligação à fibronectina (fnb) de staphylococcal aureus (s. aureus); e molécula isolada de ácido nucléico que codifica uma fnb alterada de s. aureus
TW200613554A (en)	2004-06-17	2006-05-01	Wyeth Corp	Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
CN101060859B (zh)	2004-10-06	2011-11-09	米迪缪尼有限公司	冷藏温度稳定的流感疫苗组合物
EP2213298A3 (en)	2004-10-21	2011-07-20	Wyeth LLC	Immunogenic compositions of staphylococcus epidermidis polypeptide and polynucleotide antigens
US7709001B2 (en)	2005-04-08	2010-05-04	Wyeth Llc	Multivalent pneumococcal polysaccharide-protein conjugate composition
EP2425856A1 (en)	2005-04-08	2012-03-07	Wyeth LLC	Multivalent pneumococcal polysaccharide-protein conjugate composition
TW200806315A (en)	2006-04-26	2008-02-01	Wyeth Corp	Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
PT2495307T (pt)	2006-07-13	2018-05-10	Wyeth Llc	Produção do fator ix de coagulação com padrão melhorado de glicosilação
US8192951B2 (en)	2006-11-03	2012-06-05	Wyeth Llc	Glycolysis-inhibiting substances in cell culture
AR064642A1 (es)	2006-12-22	2009-04-15	Wyeth Corp	Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
ES2541454T3 (es)	2007-03-02	2015-07-20	Wyeth Llc	Uso de cobre y glutamato en cultivos celulares para producción de polipéptidos
US20120128684A1 (en)	2008-08-25	2012-05-24	Burnham Institute For Medical Research	Conserved Hemagglutinin Epitope, Antibodies to the Epitope and Methods of Use
ES2648231T3 (es)	2008-11-05	2017-12-29	Wyeth Llc	Composición inmunogénica de múltiples componentes para la prevención de la enfermedad por estreptococos beta hemolíticos (EBH)
JP5693460B2 (ja)	2008-11-12	2015-04-01	セラクローンサイエンシーズ，インコーポレイテッド	ヒトＭ２ｅペプチド免疫原
JP2013526866A (ja)	2010-05-19	2013-06-27	バイオプロパティーズピーティーワイリミテッド	弱毒化マイコプラズマに関する方法
MX2012013664A (es)	2010-06-04	2013-01-24	Wyeth Llc	Formulaciones de vacuna.
CN103189071A (zh)	2010-08-23	2013-07-03	惠氏有限责任公司	脑膜炎萘瑟氏菌rLP2086抗原的稳定制剂
EP3056212B1 (en)	2010-09-10	2019-04-03	Wyeth LLC	Non-lipidated variants of neisseria meningitidis orf2086 antigens
ITMI20111182A1 (it)	2011-06-28	2012-12-29	Canio Buonavoglia	Vaccino per coronavirus canino
MX2018011291A (es)	2012-03-09	2023-01-31	Pfizer	Composiciones de neisseria meningitidis y metodos de las mismas.
SA115360586B1 (ar)	2012-03-09	2017-04-12	فايزر انك	تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
KR102057217B1 (ko)	2012-06-20	2020-01-22	에스케이바이오사이언스 주식회사	다가 폐렴구균 다당류-단백질 접합체 조성물
MX2015000789A (es)	2012-07-19	2015-05-07	Zoetis Llc	Composiciones de virus de la gripe bovina.
WO2014018724A1 (en)	2012-07-27	2014-01-30	Zoetis Llc	Tick toxin compositions
CN104661684B (zh)	2012-08-16	2018-03-20	辉瑞公司	糖缀合方法和组合物
KR20140075196A (ko)	2012-12-11	2014-06-19	에스케이케미칼주식회사	다가 폐렴구균 다당류-단백질 접합체 조성물
KR20140075201A (ko)	2012-12-11	2014-06-19	에스케이케미칼주식회사	다가 폐렴구균 다당류-단백질 접합체 조성물
ES2685894T3 (es)	2013-03-08	2018-10-15	Pfizer Inc.	Polipéptidos de fusión inmunogénicos
AU2014234982A1 (en)	2013-03-15	2015-09-24	Zoetis Services Llc	Cross-protection of bovines against B. trehalosi infection by a multi-valent vaccine
MX369534B (es)	2013-09-08	2019-11-11	Pfizer	Composiciones de neisseria meningitidis y sus metodos.
SI3583947T1 (sl)	2014-01-21	2024-01-31	Pfizer Inc.	Kapsularni polisaharidi streptococcus pneumoniae in njihovi konjugati
EP3957321A3 (en)	2014-01-21	2022-07-13	Pfizer Inc.	Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
JP2017505792A (ja)	2014-02-14	2017-02-23	ファイザー・インク	免疫原性糖タンパク質コンジュゲート
KR20190049940A (ko)	2015-02-19	2019-05-09	화이자 인코포레이티드	나이세리아 메닌지티디스 조성물 및 그의 방법
US11389518B2 (en)	2015-08-14	2022-07-19	Zoetis Services Llc	Mycoplasma bovis compositions
CA3010977A1 (en)	2016-01-11	2017-07-20	Zoetis Services Llc	Novel cross protective vaccine compositions for porcine epidemic diarrhea virus
US11191822B2 (en)	2016-06-22	2021-12-07	MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.	Pneumococcal polysaccharide-protein conjugate composition
EP3269385A1 (en)	2016-07-12	2018-01-17	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Pneumococcal polysaccharide-protein conjugate composition
SG10202111092UA (en)	2017-01-31	2021-11-29	Pfizer	Neisseria meningitidis compositions and methods thereof
GB201703529D0 (en)	2017-03-06	2017-04-19	Cambridge Entpr Ltd	Vaccine composition
US10525119B2 (en)	2017-03-31	2020-01-07	Boston Medical Center Corporation	Methods and compositions using highly conserved pneumococcal surface proteins
KR20200041311A (ko)	2017-06-23	2020-04-21	노소코미얼 백신 코포레이션	면역원성 조성물
EP3574915A1 (en)	2018-05-29	2019-12-04	Neovacs	Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il 13 expression or activity
CN114728050A (zh)	2019-07-31	2022-07-08	圣诺菲·帕斯图尔公司	多价肺炎球菌多糖-蛋白质缀合物组合物及其使用方法
IL297244A (en)	2020-04-16	2022-12-01	Parimmune Sas	Schistosoma-derived 28-kilodalton gst proteins for the treatment of vasculitis
EP3900739A1 (en)	2020-04-21	2021-10-27	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Synthetic streptococcus pneumoniae saccharide conjugates to conserved membrane protein
US20230364232A1 (en)	2020-09-17	2023-11-16	Neovacs	IMMUNOGENIC PRODUCT COMPRISING AN IgE FRAGMENT FOR TREATING IgE-MEDIATED INFLAMMATORY DISORDERS
WO2024069420A2 (en)	2022-09-29	2024-04-04	Pfizer Inc.	Immunogenic compositions comprising an rsv f protein trimer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL101715A (en) *	1991-05-02	2005-06-19	Amgen Inc	Recombinant dna-derived cholera toxin subunit analogs
GB9513371D0 (en) *	1995-06-30	1995-09-06	Biocine Spa	Immunogenic detoxified mutant toxins
CA2227871A1 (en) *	1995-07-26	1997-02-13	Maxim Pharmaceuticals, Inc.	Mucosal delivery of polynucleotides
GB9603314D0 (en) *	1996-02-16	1996-04-17	Biocine Spa	Immunogenic detoxified mutant toxins
WO1998045324A1 (en) *	1997-04-04	1998-10-15	The Uab Research Foundation	Use of cholera toxin mutants as mucosal adjuvants

1999
- 1999-09-30 CN CNB998115576A patent/CN1197618C/zh not_active Expired - Fee Related
- 1999-09-30 AU AU64039/99A patent/AU770333B2/en not_active Ceased
- 1999-09-30 DK DK99951639T patent/DK1117435T3/da active
- 1999-09-30 AT AT99951639T patent/ATE378066T1/de not_active IP Right Cessation
- 1999-09-30 PT PT99951639T patent/PT1117435E/pt unknown
- 1999-09-30 EP EP99951639A patent/EP1117435B1/en not_active Expired - Lifetime
- 1999-09-30 WO PCT/US1999/022520 patent/WO2000018434A1/en active IP Right Grant
- 1999-09-30 CA CA2344740A patent/CA2344740C/en not_active Expired - Fee Related
- 1999-09-30 IL IL14223199A patent/IL142231A0/xx unknown
- 1999-09-30 KR KR1020017003968A patent/KR100659803B1/ko not_active IP Right Cessation
- 1999-09-30 DE DE69937571T patent/DE69937571T2/de not_active Expired - Lifetime
- 1999-09-30 ES ES99951639T patent/ES2293735T3/es not_active Expired - Lifetime
- 1999-09-30 MX MXPA01003228A patent/MXPA01003228A/es not_active IP Right Cessation
- 1999-09-30 JP JP2000571951A patent/JP4673974B2/ja not_active Expired - Fee Related
- 1999-09-30 BR BR9914160-4A patent/BR9914160A/pt not_active Application Discontinuation
2001
- 2001-03-25 IL IL142231A patent/IL142231A/en not_active IP Right Cessation
2008
- 2008-02-01 CY CY20081100125T patent/CY1107276T1/el unknown

Also Published As

Publication number	Publication date
CY1107276T1 (el)	2012-11-21
IL142231A (en)	2010-05-31
WO2000018434A1 (en)	2000-04-06
EP1117435A1 (en)	2001-07-25
JP2002525093A (ja)	2002-08-13
AU6403999A (en)	2000-04-17
MXPA01003228A (es)	2003-06-24
CA2344740C (en)	2011-11-22
PT1117435E (pt)	2008-02-21
BR9914160A (pt)	2001-06-26
JP4673974B2 (ja)	2011-04-20
CN1320043A (zh)	2001-10-31
ATE378066T1 (de)	2007-11-15
IL142231A0 (en)	2002-03-10
CA2344740A1 (en)	2000-04-06
DE69937571D1 (de)	2007-12-27
CN1197618C (zh)	2005-04-20
ES2293735T3 (es)	2008-03-16
KR100659803B1 (ko)	2006-12-19
DE69937571T2 (de)	2008-09-04
AU770333B2 (en)	2004-02-19
EP1117435B1 (en)	2007-11-14
KR20010085859A (ko)	2001-09-07

Publication	Publication Date	Title
DK1117435T3 (da)	2008-03-17	Muteret cholera-holotoxin som adjuvans
DE60234695D1 (de)	2010-01-21	Mutantenformen von cholera holotoxin als adjuvans
MXPA03011135A (es)	2004-09-08	Formas mutantes de holotoxina de colera como adyuvante.
BR9906927A (pt)	2001-11-20	Proteìnas de neisseria meningitidis
DE60044005D1 (de)	2010-04-22	85 kDa Antigen von Neisseria
ATE297190T1 (de)	2005-06-15	Mikroemulsionen mit adsorbierten makromolekülen und mikropartikeln
DK1800692T3 (da)	2011-03-28	Immunologiske sammensætninger og vacciner indeholdende N-formyl-methionyl-peptid som adjuvans
WO2004083251A3 (en)	2004-12-23	Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
NO20054701L (no)	1995-09-22	Vaksinesammensetninger som inneholder 3-0-deacetylert monofosforyl lipid A
AU1854197A (en)	1997-08-28	Adjuvant properties of poly(amidoamine) dendrimers
GB9909077D0 (en)	1999-06-16	Novel compositions
DE60226175D1 (de)	2008-05-29	Mycobakterieller impfstoff
GEP20053446B (en)	2005-02-25	Adjuvant Combination Formulations
WO2003086277A3 (en)	2007-03-01	Attenuated gram negative bacteria
WO2000050073A3 (en)	2001-02-22	Caulobacter lps immunoadjuvant
FI934331A (fi)	1993-10-01	Nya proteaser
DK0757556T3 (da)	2006-10-02	Borrelia Burgdorferi-bakterin
DK1350796T3 (da)	2009-03-02	Attenuerede gramnegative bakterier
DE60232413D1 (en)	2009-07-02	Ltb4 als adjuvans für impfstoffe
ATE195427T1 (de)	2000-09-15	Pertussistoxin enthaltender influenzaimpfstoff
RU2227043C2 (ru)	2004-04-20	Антигены neisseria meningitidis и композиции